(Q36653588)

15 August 2017

1 reference

title

The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma (English)

1 reference

15 August 2017

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

5 November 2022

author name string

J. O. Armitage

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1710488

5 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1710488

5 November 2022

publication date

1 January 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:S0923753420315933?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

https://api.elsevier.com/content/article/PII:S0923753420315933?httpAccept=text/plain

5 November 2022

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

http://academic.oup.com/annonc/article-pdf/2/suppl_1/37/536723/2-suppl_1-37.pdf

5 November 2022

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

5 November 2022

1 reference

15 August 2017

volume

2 Suppl 1

1 reference

15 August 2017

page(s)

37-41

1 reference

Combination sequential chemotherapy in advanced reticulum cell sarcoma

15 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Advanced diffuse histiocytic lymphoma, a potentially curable disease

5 November 2022

2

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma

5 November 2022

3

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

5 November 2022

4

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma

5 November 2022

5

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma

5 November 2022

6

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology

5 November 2022

8

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.

5 November 2022

9

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80)

5 November 2022

12

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

5 November 2022

13

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions

5 November 2022

14

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update

5 November 2022

15

14

104

Guglielmi

1987

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Combination Chemotherapy of Advanced Diffuse Histiocytic Lymphoma with the Six-Drug COP-BLAM Regimen

5 November 2022

16

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

5 November 2022

18

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

5 November 2022

19

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

5 November 2022

20

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy

5 November 2022

21

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

5 November 2022

22

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Interpretation of clinical trials in diffuse large-cell lymphoma

5 November 2022

23

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma

5 November 2022

28

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma

5 November 2022

29

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma

5 November 2022

31

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas

5 November 2022

32

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy

5 November 2022

33

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial

5 November 2022

34

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas

5 November 2022

35

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

5 November 2022

36

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing Age

5 November 2022

37

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas

5 November 2022

39

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian Study

5 November 2022

40

1 reference

https://api.crossref.org/works/10.1093/ANNONC/2.SUPPL_1.37

5 November 2022

Identifiers

1 reference

15 August 2017

1 reference